These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 34228644)

  • 21. Editorial: The State-of-Art in Immuno-Oncology, What to Do With Glioblastoma?
    Cui X; Wang Q; Kang C
    Front Immunol; 2021; 12():788733. PubMed ID: 34777399
    [No Abstract]   [Full Text] [Related]  

  • 22. Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39.
    Takenaka MC; Gabriely G; Rothhammer V; Mascanfroni ID; Wheeler MA; Chao CC; Gutiérrez-Vázquez C; Kenison J; Tjon EC; Barroso A; Vandeventer T; de Lima KA; Rothweiler S; Mayo L; Ghannam S; Zandee S; Healy L; Sherr D; Farez MF; Prat A; Antel J; Reardon DA; Zhang H; Robson SC; Getz G; Weiner HL; Quintana FJ
    Nat Neurosci; 2019 May; 22(5):729-740. PubMed ID: 30962630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metabolic remodeling contributes towards an immune-suppressive phenotype in glioblastoma.
    Kesarwani P; Prabhu A; Kant S; Chinnaiyan P
    Cancer Immunol Immunother; 2019 Jul; 68(7):1107-1120. PubMed ID: 31119318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting glioblastoma with NK cells and mAb against NG2/CSPG4 prolongs animal survival.
    Poli A; Wang J; Domingues O; Planagumà J; Yan T; Rygh CB; Skaftnesmo KO; Thorsen F; McCormack E; Hentges F; Pedersen PH; Zimmer J; Enger PØ; Chekenya M
    Oncotarget; 2013 Sep; 4(9):1527-46. PubMed ID: 24127551
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glioblastoma-derived mechanisms of systemic immunosuppression.
    Waziri A
    Neurosurg Clin N Am; 2010 Jan; 21(1):31-42. PubMed ID: 19944964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in the tumor microenvironment and outcome for TME-targeting therapy in glioblastoma: A pilot study.
    Ali S; Borin TF; Piranlioglu R; Ara R; Lebedyeva I; Angara K; Achyut BR; Arbab AS; Rashid MH
    PLoS One; 2021; 16(2):e0246646. PubMed ID: 33544755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Local Intracerebral Immunomodulation Using Interleukin-Expressing Mesenchymal Stem Cells in Glioblastoma.
    Mohme M; Maire CL; Geumann U; Schliffke S; Dührsen L; Fita K; Akyüz N; Binder M; Westphal M; Guenther C; Lamszus K; Hermann FG; Schmidt NO
    Clin Cancer Res; 2020 Jun; 26(11):2626-2639. PubMed ID: 31988196
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Dynamics of Interactions Among Immune and Glioblastoma Cells.
    Eder K; Kalman B
    Neuromolecular Med; 2015 Dec; 17(4):335-52. PubMed ID: 26224516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM.
    Ge H; Mu L; Jin L; Yang C; Chang YE; Long Y; DeLeon G; Deleyrolle L; Mitchell DA; Kubilis PS; Lu D; Qi J; Gu Y; Lin Z; Huang J
    Int J Cancer; 2017 Oct; 141(7):1434-1444. PubMed ID: 28612394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. TrkB-containing exosomes promote the transfer of glioblastoma aggressiveness to YKL-40-inactivated glioblastoma cells.
    Pinet S; Bessette B; Vedrenne N; Lacroix A; Richard L; Jauberteau MO; Battu S; Lalloué F
    Oncotarget; 2016 Aug; 7(31):50349-50364. PubMed ID: 27385098
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hybrids by tumor-associated macrophages × glioblastoma cells entail nuclear reprogramming and glioblastoma invasion.
    Cao MF; Chen L; Dang WQ; Zhang XC; Zhang X; Shi Y; Yao XH; Li Q; Zhu J; Lin Y; Liu S; Chen Q; Cui YH; Zhang X; Bian XW
    Cancer Lett; 2019 Feb; 442():445-452. PubMed ID: 30472185
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma.
    De Leo A; Ugolini A; Yu X; Scirocchi F; Scocozza D; Peixoto B; Pace A; D'Angelo L; Liu JKC; Etame AB; Rughetti A; Nuti M; Santoro A; Vogelbaum MA; Conejo-Garcia JR; Rodriguez PC; Veglia F
    Immunity; 2024 May; 57(5):1105-1123.e8. PubMed ID: 38703775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment.
    van den Bossche WBL; Kleijn A; Teunissen CE; Voerman JSA; Teodosio C; Noske DP; van Dongen JJM; Dirven CMF; Lamfers MLM
    Neuro Oncol; 2018 Oct; 20(11):1494-1504. PubMed ID: 29796615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapamycin and hydroxychloroquine combination alters macrophage polarization and sensitizes glioblastoma to immune checkpoint inhibitors.
    Hsu SPC; Chen YC; Chiang HC; Huang YC; Huang CC; Wang HE; Wang YS; Chi KH
    J Neurooncol; 2020 Feb; 146(3):417-426. PubMed ID: 32020472
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy for Glioblastoma: Current Progress and Challenges.
    Yu MW; Quail DF
    Front Immunol; 2021; 12():676301. PubMed ID: 34054867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGL2 as a Multimodality Regulator of Tumor-Mediated Immune Suppression and Therapeutic Target in Gliomas.
    Yan J; Kong LY; Hu J; Gabrusiewicz K; Dibra D; Xia X; Heimberger AB; Li S
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10.
    Ravi VM; Neidert N; Will P; Joseph K; Maier JP; Kückelhaus J; Vollmer L; Goeldner JM; Behringer SP; Scherer F; Boerries M; Follo M; Weiss T; Delev D; Kernbach J; Franco P; Schallner N; Dierks C; Carro MS; Hofmann UG; Fung C; Sankowski R; Prinz M; Beck J; Salié H; Bengsch B; Schnell O; Heiland DH
    Nat Commun; 2022 Feb; 13(1):925. PubMed ID: 35177622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extracellular Matrix Protein Tenascin C Increases Phagocytosis Mediated by CD47 Loss of Function in Glioblastoma.
    Ma D; Liu S; Lal B; Wei S; Wang S; Zhan D; Zhang H; Lee RS; Gao P; Lopez-Bertoni H; Ying M; Li JJ; Laterra J; Wilson MA; Xia S
    Cancer Res; 2019 May; 79(10):2697-2708. PubMed ID: 30898840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phospho-mTOR expression in human glioblastoma microglia-macrophage cells.
    Lisi L; Ciotti GMP; Chiavari M; Pizzoferrato M; Mangiola A; Kalinin S; Feinstein DL; Navarra P
    Neurochem Int; 2019 Oct; 129():104485. PubMed ID: 31195027
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.